Hyperphosphatemia Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Novel Therapeutics and Rising CKD Burden | DelveInsight
The hyperphosphatemia market is projected to witness steady growth, driven by the increasing global prevalence of chronic kidney disease, diabetes, and hypertension, along with a growing dialysis patient population. Additionally, the emergence of novel therapies such as TS-172 (Taisho Pharmaceutical), AP-301 (Alebund Pharmaceuticals), Oxylanthanum Carbonate (Unicycive Therapeutics), AP306 (R1 Therapeutics), and others, targeting intestinal phosphate absorption pathways, such as NHE3 inhibitors, is anticipated to transform the treatment landscape during the forecast period.
LAS VEGAS, Aug. 5, 2026 /PRNewswire/ -- Recently published Hyperphosphatemia Market Insights report includes a comprehensive understanding of current treatment practices, hyperphosphatemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Hyperphosphatemia Market Summary
Discover what is the future of the hyperphosphatemia drugs market @ https://www.delveinsight.com/report-store/hyperphosphatemia-market
Key Factors Driving the Growth of the Hyperphosphatemia Market
Aparna Thakur, Project Manager of Forecasting at DelveInsight, said that the future growth of the hyperphosphatemia drugs market is anticipated through next-generation phosphate binders, such as oxylanthanum carbonate, that aim to reduce pill burden and improve patient adherence.
Hyperphosphatemia Market Analysis
Hyperphosphatemia Competitive Landscape
Some of the hyperphosphatemia drugs under development include TS-172 (Taisho Pharmaceutical), AP-301 (Alebund Pharmaceuticals), Oxylanthanum Carbonate (Unicycive Therapeutics), AP306 (R1 Therapeutics), and others.
Taisho Pharmaceutical is evaluating TS-172 in a Phase III clinical trial (NCT06745531), designed as a randomized, double-blind, placebo-controlled study to assess its efficacy and safety in patients with hyperphosphatemia receiving hemodialysis.
Unicycive Therapeutics' Oxylanthanum carbonate (OLC) is an investigational therapy being developed through the FDA's 505(b)(2) regulatory pathway. Positioned as a potential best-in-class treatment, OLC is expected to improve patient adherence by reducing pill burden, requiring fewer and smaller tablets per dose that are swallowed rather than chewed compared with currently available phosphate binders.
R1 Therapeutics' AP306 is a first-in-class, broad-spectrum phosphate transporter inhibitor being developed as a standalone therapy for managing hyperphosphatemia in patients with CKD. Unlike currently approved phosphate-lowering treatments, which primarily reduce phosphate absorption through phosphate binding and other mechanisms that target passive transport, AP306 uniquely inhibits the active transport of phosphate, making it the only investigational therapy with this mechanism of action for CKD.
Formerly known as EOS789, AP306 was initially discovered and advanced by Chugai Pharmaceutical Co., Ltd. before being licensed to Alebund Pharmaceuticals. The therapy is currently supported by active Investigational New Drug (IND) applications in both the United States and China, facilitating its ongoing clinical development.
The anticipated launch of these emerging therapies are poised to transform the hyperphosphatemia market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the hyperphosphatemia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the hyperphosphatemia drugs market size @ Hyperphosphatemia Drugs
Recent Developments in the Hyperphosphatemia Market
Hyperphosphatemia Epidemiology Segmentation
The hyperphosphatemia epidemiology section provides insights into the historical and current hyperphosphatemia patient pool and forecasted trends for the leading markets. Among children with oncologic disorders who received liposomal amphotericin, nearly 45% of children developed hyperphosphatemia.
The hyperphosphatemia treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Hyperphosphatemia Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Hyperphosphatemia Epidemiology Segmentation
Total Prevalent Cases of Chronic Kidney Disease (CKD), Total Diagnosed Prevalent Cases of CKD, Stage-specific Distribution of CKD, Total Prevalent Cases of End-Stage Renal Disease (ESRD), Number of ESRD patients undergoing Dialysis, and Total Prevalent Cases of Hyperphosphatemia
Key Hyperphosphatemia Companies
Taisho Pharmaceutical, Alebund Pharmaceuticals, Unicycive Therapeutics, R1 Therapeutics, Ardelyx, Sanofi, Takeda Pharmaceutical, and others
Key Hyperphosphatemia Therapies
TS-172, AP-301, Oxylanthanum Carbonate, AP306, XPHOZAH, RENVELA, FOSRENOL, and others
Scope of the Hyperphosphatemia Market Report
Download the report to understand the new drugs for hyperphosphatemia @ Hyperphosphatemia Clinical Trials
Table of Contents
1
Hyperphosphatemia Market Key Insights
2
Hyperphosphatemia Market Report Introduction
3
Executive Summary of Hyperphosphatemia
4
Key Events of Hyperphosphatemia
5
Epidemiology and Market Methodology of Hyperphosphatemia
6
Hyperphosphatemia Market Overview at a Glance
6.1
Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
6.2
Market Share of Hyperphosphatemia By Therapies (%) in the 7MM in 2025
6.3
Market Share of Hyperphosphatemia By Therapies (%) in the 7MM in 2036
7
Disease Background and Overview of Hyperphosphatemia
7.1
Introduction
7.2
Causes
7.3
Signs and Symptoms
7.4
Developmental and Clinical Aspects
7.5
Pathophysiology
7.6
Clinical manifestations
7.7
Diagnosis
8
Treatment and Guidelines of Hyperphosphatemia
8.1
Treatment Algorithm
9
Epidemiology and Patient Population of Hyperphosphatemia
9.1
Key Findings
9.2
Assumptions and Rationale: The 7MM
9.2.1
Total Incident cases of Hyperphosphatemia in the 7MM
9.3
The US
9.3.1
Total Prevalent Cases of Hyperphosphatemia in the United States
9.3.2
Total Diagnosed Prevalent Cases of Chronic Kidney Disease in the United States
9.3.3
Stage-specific Distribution of Chronic Kidney Disease in the United States
9.3.4
Total Prevalent Cases of End-Stage Renal Disease in the United States
9.3.5
Number of ESRD Patients Undergoing Dialysis in the United States
9.3.6
Total Prevalent Cases of Hyperphosphatemia in the United States
9.4
EU4 and the UK
9.5
Japan
10
Patient Journey of Hyperphosphatemia
11
Marketed Hyperphosphatemia Drugs
11.1
Competitive Landscape: Marketed Therapies
11.2
Tenapanor (XPHOZAH): Ardelyx
11.2.1
Product Description
11.2.2
Regulatory Milestones
11.2.3
Other Developmental Activities
11.2.4
Summary of Pivotal Trials
11.2.5
Analyst Views
11.3
Lanthanum Carbonate (FOSRENOL): Takeda Pharmaceutical
List to be continued in the report….
12.
Emerging Hyperphosphatemia Drugs
12.1
Competitive Landscape of Emerging Therapies
12.2
Oxylanthanum Carbonate: Unicycive Therapeutics
12.2.1
Product Description
12.2.2
Other Development Activities
12.2.3
Clinical Development
12.2.4
Safety and Efficacy
12.2.5
Analyst Views
12.3
AP-301: Alebund Pharmaceuticals
List to be continued in the report….
13
Hyperphosphatemia Market: Seven Major Market Analysis
13.1
Key Findings
13.2
Hyperphosphatemia Market Outlook
13.3
Conjoint Analysis
13.4
Key Hyperphosphatemia Market Forecast Assumptions
13.5
Total Market Size of Hyperphosphatemia in the 7MM
13.6
The United States Hyperphosphatemia Market Size
13.6.1
Total Market Size of Hyperphosphatemia in the United States
13.6.2
Market Size of Hyperphosphatemia by Therapies in the United States
13.7
EU4 and the UK Hyperphosphatemia Market Size
13.8
Japan Hyperphosphatemia Market Size
14
Unmet Needs of Hyperphosphatemia
15
SWOT Analysis of Hyperphosphatemia
16
KOL Views of Hyperphosphatemia
16.1
Expert/KOL Interview Highlights
17
Market Access and Reimbursement of Hyperphosphatemia
17.1
United States
17.2
EU4 and the UK
17.3
Japan
17.4
Summary and comparison of Market Access and Pricing Policy Developments in 2025
17.5
Market Access and Reimbursement of Hyperphosphatemia Therapies
18
Bibliography
19
Hyperphosphatemia Market Report Methodology
Related Reports
Hyperphosphatemia Clinical Trial Analysis
Hyperphosphatemia Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hyperphosphatemia companies, including Taisho Pharmaceutical Co., Ltd., Alebund Pharmaceuticals, Jemincare, and others.
Chronic Kidney Disease Market
Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key CKD companies, including ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc., Lexicon Pharmaceuticals, Sanofi, and others.
Chronic Kidney Disease Clinical Trial Analysis
Chronic Kidney Disease Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CKD companies, including Novo Nordisk, Prokidney, Kibow Pharma, XORTX Therapeutics, Lisata Therapeutics, Unicycive Therapeutics, Novo Nordisk, Bayer, AstraZeneca, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Boehringer Ingelheim, SCOHIA PHARMA, Regeneron Pharmaceuticals, UnicoCell Biomed, OccuRx, Disc Medicine, Shandong Suncadia Medicine, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, Healx, Benevolent, and others.
End-stage Renal Disease Market
End-stage Renal Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key ESRD companies, including Medtronic PLC, B. Braun SE, Asahi Kasei Medical Co. Ltd, Cantel Medical (STERIS), Nikkiso Co. Ltd, Nipro Corporation, Fresenius SE & Co. KGaA, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP